Morgan Petronelli

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

The FDA and CDC announced the availability of additional doses of nirsevimab-alip for infants at high-risk of infection.